Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979887 · ClinicalTrials.gov registry record
Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction
A clinical trial of Meibomian Glands, sponsored by Allergan.
- Completed
- Registry status
- 75
- Enrollment target
- 2
- Study locations
NCT01979887: Completed study of Meibomian Glands, sponsored by Allergan.
NCT01979887 is a study of Meibomian Glands that has completed, run by Allergan. The registered enrollment target is 75 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01979887, a study of Meibomian Glands, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
Conditions Studied
Interventions
- PROCEDURE Meibum Expression
Study Locations (2)
Texas
- - Houston
Other
- - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-07 |
What the finished NCT01979887 record still lists
NCT01979887 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 1 condition, with Meibomian Glands appearing as the primary indexed condition, and to 1 intervention - of which Meibum Expression is the first listed.
NCT01979887 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT01979887 about?
NCT01979887 is a clinical study titled "Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction". This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
What is the current status of trial NCT01979887?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2013-11. Estimated completion is 2014-07.
What conditions does trial NCT01979887 study?
This clinical trial studies the following conditions: Meibomian Glands.
What interventions are being tested in trial NCT01979887?
The interventions under investigation include: Meibum Expression (PROCEDURE).
Who is sponsoring clinical trial NCT01979887?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01979887 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia